<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03949517</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-48213</org_study_id>
    <secondary_id>PROS0093</secondary_id>
    <secondary_id>IRB-48213</secondary_id>
    <nct_id>NCT03949517</nct_id>
  </id_info>
  <brief_title>A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy</brief_title>
  <official_title>A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrei Iagaru</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>General Electric</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine whether the combination of imaging agents 68-Ga&#xD;
      RM2 and 68-Ga PMSA11 is better at assessing response to high intensity focused ultrasound&#xD;
      (HIFU) or high dose rate (HDR) local therapy than standard imaging or biopsy in patients with&#xD;
      known prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To determine feasibility of 68Ga-PSMA-11 PET/MRI and 68Ga-RM2 PET/MRI for&#xD;
      evaluation of HIFU or HDR local therapy in patients with known prostate cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positron emission tomography (PET) based of Assessment of Local Therapeutic Response</measure>
    <time_frame>12 months</time_frame>
    <description>Therapeutic response to high intensity focused ultrasound (HIFU) or high dose rate (HDR) will be assessed by 68-Ga PSMA 11 and 68-Ga RM2 PET scans. The outcome is the number of participants without dispersion, by randomization schedule, for which an assessment of PET based therapeutic response to HIFU or HDR is successfully obtained.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>68-Ga RM2+68-Ga PSMA11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>68-Ga RM2 first followed by 68-Ga PSMA11 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>68-Ga PSMA11+68-Ga RM2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>68-Ga PSMA11 first followed by 68-Ga RM2 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68-Ga RM2</intervention_name>
    <description>Radioactive agent</description>
    <arm_group_label>68-Ga PSMA11+68-Ga RM2</arm_group_label>
    <arm_group_label>68-Ga RM2+68-Ga PSMA11</arm_group_label>
    <other_name>68Ga-DOTA-4-amino-1-carboxymethyl-piperidine-DPhe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2</other_name>
    <other_name>68Ga-DOTA-Bombesin</other_name>
    <other_name>BAY86-7548</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68-Ga PSMA11</intervention_name>
    <description>Radioactive agent</description>
    <arm_group_label>68-Ga PSMA11+68-Ga RM2</arm_group_label>
    <arm_group_label>68-Ga RM2+68-Ga PSMA11</arm_group_label>
    <other_name>DFKZ 11</other_name>
    <other_name>HBED CC PSMA</other_name>
    <other_name>Heidelberg compound</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Investigational software and coils in PET/MR Scan</intervention_name>
    <description>Investigational software and coils in PET/MR Scan by General Electric Healthcare</description>
    <arm_group_label>68-Ga PSMA11+68-Ga RM2</arm_group_label>
    <arm_group_label>68-Ga RM2+68-Ga PSMA11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET/MRI</intervention_name>
    <description>Positron emission tomography (PET)/Magnetic resonance imaging (MRI) Scan</description>
    <arm_group_label>68-Ga PSMA11+68-Ga RM2</arm_group_label>
    <arm_group_label>68-Ga RM2+68-Ga PSMA11</arm_group_label>
    <other_name>Positron emission tomography (PET)/Magnetic resonance imaging (MRI)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Known prostate cancer&#xD;
&#xD;
          -  Planned HIFU or HDR local therapy&#xD;
&#xD;
          -  Able to provide written consent&#xD;
&#xD;
          -  Karnofsky performance status of 50 (or Eastern Cooperative Oncology Group (ECOG)&#xD;
             /World Health Organization (WHO) equivalent)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not capable of getting PET study due to weight, claustrophobia, or inability&#xD;
             to lay still for the duration of the exam&#xD;
&#xD;
          -  Metallic implants (contraindicated for MRI)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei H Iagaru, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brittney Williams</last_name>
    <phone>650-497-8588</phone>
    <email>bw718@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahryar Niknam</last_name>
      <phone>650-721-4080</phone>
      <email>sniknam@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrei Iagaru</investigator_full_name>
    <investigator_title>Professor of Radiology (Nuclear Medicine)</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piperidine</mesh_term>
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
    <mesh_term>Bombesin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

